- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03936361
Statins In Intracerbral Hemorrhage (SATURN)
STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTS
The SATURN trial aims to determine whether continuation vs. discontinuation of statin drugs after spontaneous lobar intracerebral hemorrhage (ICH) is the best strategy; and whether the decision to continue/discontinue statins should be influenced by an individual's Apolipoprotein-E (APOE) genotype.
An MRI ancillary study (SATURN MRI), in a subset of SATURN participants , will evaluate the effects of continuation vs. discontinuation of statin drugs on hemorrhagic and ischemic MRI markers of cerebral small vessel disease, and whether the presence/burden of hemorrhagic markers (i.e. cerebral microbleeds and/or cortical superficial siderosis) on baseline MRI influences the risk of ICH recurrence on/off statin therapy.
Study Overview
Detailed Description
SATURN is a multi-center, pragmatic, prospective, randomized, open-label, and blinded end-point assessment (PROBE) clinical trial. A total of 1,456 patients presenting within 7 days of a spontaneous lobar ICH while taking statins will be randomized to one of two treatment strategies: discontinuation vs. continuation of statin therapy (using the same agent and dose that they were using at ICH onset). Participating subjects will undergo baseline testing for APOE genotype and will be followed for 24 months to assess for the occurrence of recurrent symptomatic ICH or major adverse cerebro-/cardio-vascular events (MACCE) during the follow-up period. A subset of SATURN participants will participate in the optional MRI study, where they will undergo a baseline MRI within 7 days of randomization into SATURN and a repeat MRI at the end of the follow-up period.
Recruitment will take place at ~ 140 sites coordinated through the NIH/NINDS StrokeNet and the Canadian Stroke Consortium.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Magdy Selim, MD, PhD
- Phone Number: 617-632-8913
- Email: mselim@bidmc.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Beth Israel Deaconess Medical Center
-
Contact:
- Magdy Selim, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 50 years.
- Spontaneous lobar ICH confirmed by CT or MRI scan
- Patient was taking a statin drug at the onset of the qualifying/index ICH
- Randomization can be carried out within 7 days of the onset of the qualifying ICH
- Patient or legally authorized representative, after consultation with the statin prescriber, agrees to be randomized to statin continuation (restart) vs. discontinuation
Exclusion Criteria:
- Suspected secondary cause for the qualifying ICH, such as an underlying vascular abnormality or tumor, trauma, venous infarction, or hemorrhagic transformation of an ischemic infarct.
- History of recent myocardial infarction (attributed to coronary artery disease) or unstable angina within the previous 3 months
- Diabetic patients with history of myocardial infarction or coronary revascularization
- History of familial hypercholesterolemia
- Patients receiving proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors
- Known diagnosis of severe dementia
- Inability to obtain informed consent
- Patients known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, or other obvious reasons for noncompliance, such as unable to adhere to the protocol specified visits/assessments.
- Life expectancy of less than 24 months due to co-morbid terminal conditions.
- Pre-morbid mRS >3
- ICH score >3 upon presentation.
- Contraindications to continuation/resumption of statin therapy, such as significant elevations of serum creatinine kinase and/or liver transaminases, and rhabdomyolysis
- Woman of childbearing potential
- Concurrent participation in another research protocol for investigation of experimental therapy.
- Indication that withdrawal of care will be implemented for the qualifying ICH.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Statin
The same statin agent and dose that subjects were using at the time of ICH onset.
|
Statin drugs (already prescribed) at ICH onset will be either continued or discontinued by the participants following qualifying ICH
Other Names:
|
No Intervention: No-statin
Subjects will discontinue the statin agent that they were taking at the time of ICH onset.
No placebo will be prescribed for these subjects.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Recurrent symptomatic ICH
Time Frame: within 24 months
|
within 24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Major Adverse Cerebro- and Cardio-Vascular Events
Time Frame: Within 24 months
|
Within 24 months
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018C000515
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracerebral Hemorrhage
-
Wake Forest University Health SciencesActive, not recruitingStroke Hemorrhagic | Intracerebral Hemorrhage | Cerebral Edema | Intracerebral Hemorrhage, Hypertensive | Intracerebral Hemorrhage IntraparenchymalUnited States
-
Tongji HospitalUnknown
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
Beijing Tiantan HospitalBeijing Friendship Hospital; RenJi Hospital; Qilu Hospital of Shandong University and other collaboratorsRecruitingSpontaneous Intracerebral HemorrhageChina
-
University Hospital, Basel, SwitzerlandSwiss Heart FoundationActive, not recruitingIntracerebral Hemorrhage (ICH)Switzerland
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
AegisCN LLCCompletedIntracerebral Hemorrhage (ICH)United States
-
CellMed AG, a subsidiary of BTG plc.TerminatedIntracerebral Hemorrhage (ICH)Germany
-
Tang-Du HospitalRecruitingIntracerebral Hemorrhage;Circulating ExosomesChina
Clinical Trials on Statins
-
University of Colorado, DenverNational Institute of Nursing Research (NINR)CompletedCardiovascular Disease | Palliative MedicineUnited States
-
Faculty of Medicine, Tarumanagara UniversityCengkareng General HospitalCompletedHeart Failure | Arrhythmias, Cardiac | Acute Coronary Syndrome | Acute Pulmonary EdemaIndonesia
-
Pronova BioPharmaTerminated
-
Boryung Pharmaceutical Co., LtdCompletedHypertension and DyslipidemiaKorea, Republic of
-
University of Kansas Medical CenterUniversity of Missouri-Columbia; American Heart AssociationCompleted
-
Shanghai 10th People's HospitalCompleted
-
AkesoAD Pharmaceuticals Co., Ltd.CompletedHomozygous Familial HypercholesterolemiaChina
-
Karolinska InstitutetActive, not recruiting
-
University of Sao PauloMerck Sharp & Dohme LLCUnknownHeterozigous Familial HypercholesterolemiaBrazil